Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) - Zacks Research lowered their Q2 2025 earnings per share estimates for Thermo Fisher Scientific in a research note issued on Tuesday, March 18th. Zacks Research analyst R. Department now expects that the medical research company will post earnings per share of $5.59 for the quarter, down from their prior estimate of $5.60. The consensus estimate for Thermo Fisher Scientific's current full-year earnings is $23.28 per share. Zacks Research also issued estimates for Thermo Fisher Scientific's Q4 2025 earnings at $6.68 EPS, Q2 2026 earnings at $6.47 EPS and Q4 2026 earnings at $6.31 EPS.
Other equities analysts have also issued reports about the company. StockNews.com raised Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Tuesday, January 14th. Morgan Stanley increased their target price on Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an "overweight" rating in a research report on Friday, January 31st. Royal Bank of Canada set a $693.00 price target on shares of Thermo Fisher Scientific in a research report on Friday, January 31st. Bank of America cut their price objective on shares of Thermo Fisher Scientific from $675.00 to $660.00 and set a "buy" rating on the stock in a research report on Friday, December 13th. Finally, Raymond James reaffirmed an "outperform" rating and set a $667.00 price target (up previously from $650.00) on shares of Thermo Fisher Scientific in a report on Monday, February 3rd. Four analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $653.23.
Read Our Latest Stock Analysis on Thermo Fisher Scientific
Thermo Fisher Scientific Stock Performance
Shares of NYSE TMO traded up $2.53 during midday trading on Thursday, hitting $520.25. The company's stock had a trading volume of 1,099,952 shares, compared to its average volume of 1,538,823. The firm has a market cap of $196.27 billion, a P/E ratio of 31.47, a P/E/G ratio of 2.99 and a beta of 0.79. Thermo Fisher Scientific has a 1-year low of $493.30 and a 1-year high of $627.88. The firm's fifty day moving average price is $545.44 and its 200-day moving average price is $554.91. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%.
Hedge Funds Weigh In On Thermo Fisher Scientific
Institutional investors and hedge funds have recently modified their holdings of the stock. Howard Capital Management Group LLC grew its stake in shares of Thermo Fisher Scientific by 0.5% in the 3rd quarter. Howard Capital Management Group LLC now owns 54,575 shares of the medical research company's stock valued at $33,759,000 after buying an additional 286 shares in the last quarter. Principal Financial Group Inc. lifted its stake in shares of Thermo Fisher Scientific by 22.1% in the 3rd quarter. Principal Financial Group Inc. now owns 1,247,838 shares of the medical research company's stock valued at $771,876,000 after purchasing an additional 225,568 shares during the last quarter. Prospera Financial Services Inc boosted its holdings in Thermo Fisher Scientific by 19.6% in the third quarter. Prospera Financial Services Inc now owns 4,549 shares of the medical research company's stock worth $2,816,000 after purchasing an additional 746 shares in the last quarter. Avior Wealth Management LLC raised its holdings in Thermo Fisher Scientific by 0.8% during the third quarter. Avior Wealth Management LLC now owns 3,956 shares of the medical research company's stock valued at $2,447,000 after buying an additional 30 shares in the last quarter. Finally, Prospera Private Wealth LLC lifted its position in shares of Thermo Fisher Scientific by 1,868.3% in the third quarter. Prospera Private Wealth LLC now owns 9,940 shares of the medical research company's stock worth $6,149,000 after buying an additional 9,435 shares during the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.
Insider Buying and Selling
In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 3,775 shares of the firm's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the completion of the sale, the senior vice president now directly owns 10,816 shares in the company, valued at approximately $5,759,736.32. This trade represents a 25.87 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Stephen Williamson sold 9,825 shares of the company's stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $5,753,421.75. Following the completion of the transaction, the chief financial officer now owns 27,296 shares in the company, valued at $15,984,264.64. This represents a 26.47 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 23,900 shares of company stock valued at $13,106,062. Company insiders own 0.34% of the company's stock.
Thermo Fisher Scientific Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, March 14th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.33%. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.39. Thermo Fisher Scientific's payout ratio is currently 10.41%.
About Thermo Fisher Scientific
(
Get Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Featured Stories
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
